The US is making measles great again, so treatment options are needed for the most vulnerable.
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease.
But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it’s even more uncertain if those who refuse vaccines would take such treatments.
Fueled by large outbreaks in South Carolina and Utah, the US had already surpassed last year’s 2,289 measles cases, and it’s only July. For comparison, there were just 285 cases in all of 2024.
Ars Technica – All content Read More
About The Author
